Third-line chemotherapy with mitomycin, vinblastine, and carmustine (BCNU) in refractory breast carcinoma: A pilot study

A. Veronesi, U. Tirelli, E. Galligioni, M. G. Trovò, D. Crivellari, M. Donatella Magri, M. Roncadin, S. Tumolo, E. Grigoletto

Research output: Contribution to journalArticle

Abstract

Twenty-four patients with breast carcinoma refractory to successive hormonal treatment, CMF (cyclophosphamide, methotrexate, and 5-FU) or its modifications, and AV (doxorubicin and vincristine) were treated iv with 3 mg/m2 of vinblastine, 4 mg/m2 of mitomycin, and 50 mg/m2 of carmustine (BCNU) administered simultaneously every 14 days. This regimen was of little benefit in the 22 evaluable patients, yielding a 9% response rate.

Original languageEnglish
Pages (from-to)559-561
Number of pages3
JournalCancer Treatment Reports
Volume66
Issue number3
Publication statusPublished - 1982

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Third-line chemotherapy with mitomycin, vinblastine, and carmustine (BCNU) in refractory breast carcinoma: A pilot study'. Together they form a unique fingerprint.

  • Cite this

    Veronesi, A., Tirelli, U., Galligioni, E., Trovò, M. G., Crivellari, D., Donatella Magri, M., Roncadin, M., Tumolo, S., & Grigoletto, E. (1982). Third-line chemotherapy with mitomycin, vinblastine, and carmustine (BCNU) in refractory breast carcinoma: A pilot study. Cancer Treatment Reports, 66(3), 559-561.